Financial

Opsens’ Japanese partner Zeon medical proceeds with Conversion of US$2 million Debenture

QUEBEC CITY, Nov. 27, 2017 /CNW Telbec/ – Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) is pleased to announce the conversion of the US$2 million debenture held by Zeon Medical Inc. (“Zeon Medical”), Opsens’ Japanese partner. Zeon Medical has been a client of Opsens since 2004. In 2012, Opsens granted Zeon Medical the exclusive distribution […]

Boston Scientific To Participate In Citi 2017 Global Healthcare Conference

MARLBOROUGH, Mass., Nov. 27, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) will participate in the Citi 2017 Global Healthcare Conference on December 7, 2017 in New York. Kevin Ballinger, executive vice president and president, interventional cardiology, and Susie Lisa, vice president, investor relations, will participate in a 40-minute question-and-answer session with the host analyst beginning at approximately 8:45 […]

CHF Solutions Prices $18M Offering

EDEN PRAIRIE, Minn., Nov. 22, 2017 (GLOBE NEWSWIRE) — CHF Solutions(NASDAQ:CHFS) announced today the pricing of an underwritten public offering of Series F convertible preferred stock, together with warrants, for gross proceeds of $18.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by CHF Solutions. The Series F […]

LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million

LONDON & SHANGHAI–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort for $190 million in cash. The CRM Business Franchise develops, […]

Neovasc Closes Offering of Units Consisting of Common Shares and Warrants and Concurrent Private Placement of Notes and Warrants

VANCOUVER, Nov. 17, 2017 /PRNewswire/ – Neovasc Inc. (NASDAQ, TSX: NVCN) is pleased to announce the closing of its previously announced underwritten offering of 6,609,588 Series A units (the “Series A Units”) and 19,066,780 Series B units (the “Series B Units” and together with the Series A Units, the “Units”) of the […]

Neovasc Announces Results for the Third Quarter of 2017

VANCOUVER, Nov. 14, 2017 /PRNewswire/ – Neovasc Inc. (NASDAQ, TSX: NVCN) today announced financial results for the third quarter ended September 30, 2017 (all figures in U.S. dollars unless otherwise indicated). “From a product perspective, our two lead devices continue to perform well, quarter after quarter; patient after patient,” commented Neovasc CEO, […]

EBR Systems, Inc. Raises $50 Million to Complete Global Heart Failure Trial

SUNNYVALE, Calif.–(BUSINESS WIRE)–EBR Systems, Inc., developer of the world’s first and only wireless cardiac pacing system for heart failure, has raised $50 million to conduct the global SOLVE-CRT study. The financing was led by Australian private equity firms M.H. Carnegie & Co. and Brandon Capital Partners and included participation by […]

Xeltis Closes $52M for Replacement Heart Valve Programs

EINDHOVEN, The Netherlands and ZURICH, November 15, 2017 /PRNewswire/ — Xeltis, a clinical-stage medical device company pioneering a restorative approach in heart valve therapy, today announced the completion of an oversubscribed EUR45 million ($52 million) Series C financing. The funding round was led by a global strategic investor with participation […]

How Medical Devices are Changing Our Perception of Precision Medicine

By Ken Dropiewski, Prime-Core Executive Search (ken@prime-core.com) When you think of precision medicine there are a few things that naturally come to mind: drugs tailored to genetics and certain other genome-based therapies. Medical devices are probably not your first thought. Earlier this year, Medtronic received approval for MR-Conditional Quadripolar Cardiac […]